Increased platelet-leukocyte-aggregate (PLA) formation has been reported in acute coronary syndromes (ACS) and during cardiopulmonary bypass, and PLA formation has been acknowledged as a possible target for antiplatelet therapy in ACS and coronary interventions. It has also been suggested as a monitoring tool for risk stratification parameters. In a controlled study design as well as under clinical conditions we investigated the effect of antiplatelet agents by flow cytometric measurement of PLA formation. We were able to demonstrate considerable reduction in PLA formation under experimental and clinical clopidogrel therapy alone or in combination with aspirin. In healthy volunteers the percentage of monocyte-PLAs decreased significantly to 55 to 75% of the baseline under clopidogrel, depending on the type and concentration of the activating agent. In patients with severe peripheral artery disease, formation of monocyte-PLAs at baseline and after stimulation with thrombin receptor activating peptide (TRAP) or adenosine diphosphate (ADP) was significantly lower under combined therapy when compared with patients under aspirin alone or without antiplatelet treatment.
Formation of platelet-leukocyte-aggregates (PLA) represents an important mechanism by which leukocytes contribute to thrombotic events and platelets to inflammatory reactions. Damage to a blood vessel results in the adhesion of platelets to the site of injury and the subsequent formation of a platelet thrombus. Interaction of leukocytes with activated platelets is coordinated by an adhesion cascade in which P-selectin binds to P-selectin glycoprotein ligand-1 (PSGL-1) on leukocytes. In vitro, binding of activated platelets to myeloid leukocytes induces expression of proinflammatory cytokines, oxidative burst, and increased surface expression of Mac- [1] [2] [3] [4] The localized accumulation of monocytes/polymorphonuclear cells in the arterial intima after prior expression of adhesion molecules triggers cellular and subcellular events. 5 Intracellular cross talk and binding of platelets to leukocytes have been investigated in various disease states and PLA formation has been proposed as a predictive marker for the outcome in several clinical conditions. Increased PLA formation has been reported in acute coronary syndromes 2, 6, 7 (ACS) and cardiopulmonary intervention. 2, [8] [9] [10] As a consequence, PLA formation has been acknowledged as a possible target for antiaggregatory therapy in ACS and coronary interventions. 11 PLA-formation has also been claimed as being useful for monitoring risk stratification parameters. 10, 12, 13 However, there are few clinical reports of drug effects on formation of PLA. From these data, it has been demonstrated that antiplatelet therapy with ticlopidine and acetylsalicylic acid (ASA) significantly reduced platelet-monocyte conjugates by 46%, associated with a decrease in Mac-1 expression by 28%.
14 ASA alone seems to have no effect on PLA formation and monocyte activation. 15 The question is whether flow cytometric measurement of PLA formation may serve as a tool for monitoring antiplatelet therapy, especially for compounds that interfere with the degranulation process or to stratify patients for risk of ACS.
INVESTIGATIONS
In a controlled study design as well as under clinical conditions, we investigated the effect of antiplatelet agents by flow cytometric measurement on PLA formation in leukocyte subpopulations. In an ex vivo in vitro design we investigated the inhibitory effect of clopidogrel in normal persons. 16 Ten healthy male volunteers (age 21 to 35 years) received clopidogrel (loading dose 2 Â 75 mg at day 1, then 75 mg o.d. from day 2 to 6). All subjects were tested for bleeding disorders (for example, von Willebrand disease) prior to the study. Blood was drawn at day 1 (baseline) and at day 6 (under clopidogrel).
Furthermore, in a cross-sectional study, we investigated the formation of PLA in 44 patients with peripheral arterial occlusive disease (PAOD, grade I according the Rutherford Classification) under clopidogrel (N ¼ 12), aspirin (N ¼ 17), their combination (N ¼ 8), and no treatment (N ¼ 7), as well as in a control group of healthy subjects (N ¼ 9). 17 In both settings, flow cytometric measurements were performed in whole blood in unstimulated samples and after stimulation with thrombin receptor activating peptide (TRAP-7, Bachem, Freiburg, Gemany) and ADP (Roche Diagnostics, Mannheim, Germany) at various concentrations (10 minutes). Samples were activated, fixed, and tested immediately after withdrawal. Erythrocytes were lysed using FACS-Lysing solution (Becton Dickinson, San Jose, CA). For PLA-analysis, we stained blood cells by triple-color immunofluorescence with the use of PE-conjugated platelet-specific CD42b mAb (Beckman-Coulter, Krefeld, Germany), PerCP-conjugated leukocyte marker CD45 (Becton Dickinson), and FITC-conjugated monocyte marker CD14 (Becton Dickonson). Flow cytometric measurements were performed using a three-color FACSCalibur flow cytometer (Becton Dickinson). Acquisition and storage of data were performed in CELLQuest TM (BectonDickinson). Leukocyte acquisition was triggered on CD45-PerCP and different leukocyte subpopulations were gated in a dot plot analysis (FL1 versus FSC). Formation of PLA was quantified by percentage and mean fluorescent intensity (MFI) of CD42b-positive cells in each leukocyte subpopulation. Nonspecific membrane immunofluorescence and background fluorescence were determined by an isotype-matched IgG-control.
RESULTS
We were able to demonstrate considerable reduction in PLA formation under experimental and clinical clopidogrel therapy alone or in combination with aspirin.
A significant reduction in the number of monocyte-PLA by clopidogrel was observed in unstimulated samples (from 9 AE 1% to 6 AE 2%, p < 0.03) or at stimulation of platelets with low TRAP and ADP concentrations (2mM). Additionally, the MFI of monocyte-PLA at day 6 decreased significantly under clopidogrel to 55 to 75% of the baseline, depending on the type and concentration of the activating agent (Fig. 1) . A distinct dose response was seen for PLA formation with TRAP.
In our clinical evaluation, formation of monocyteplatelet aggregates (percentage of monocytes with platelets attached) at baseline and after stimulation with TRAP or ADP was significantly lower in patients under combined therapy when compared with patients under aspirin alone or without antiplatelet treatment (Table 1) . Healthy subjects had significantly fewer monocyte-platelet aggregates when compared with patients without antiplatelet therapy. The MFI of the platelet mass attached to monocytes was significant lower in patients FLOW CYTOMETRY TO MONITOR PLATELET FUNCTION/KLINKHARDT, HARDER under clopidogrel or with combined therapy of clopidogrel and aspirin, compared with patients with aspirin mono therapy or no antiplatelet therapy (Fig. 2) . Differences in polymorphonuclear cells (PMNC)-PLA at baseline and after stimulation with ADP or TRAP were seen in a similar pattern as for monocytes, but the overall expression of PMNC-PLA was considerably lower than the monocyte-platelet (data not shown).
DISCUSSION
We could demonstrate in two human studies that flow cytometric measurement of PLA formation is well suited for dose response of antiplatelet agents in healthy volunteers, and it allows for discrimination of antiplatelet drug response under chronic, long-term therapy. It may also be a valuable tool for establishing the clinical significance of circulating PLAs and a qualified method to monitor antiplatelet therapy with compounds that interfere with the degranulation process. Although measurement of PLA formation seems to be a possible tool for monitoring antiplatelet therapy in long-term treatment where inflammatory responses play an important role, it is not suited for the acute, short-term situations. Flow cytometry is a very sensitive, but timeconsuming and expensive tool and needs qualified personnel with experience in handling of blood samples and preparation of platelets for flow cytometric measurements. An alternative for assessing the platelet-leukocyte axis in acute events might be the determination of the soluble CD40 ligand (by ELISA technique) which is expressed and released from platelets on activation and which was recently proposed as a marker of predictive value for the clinical outcome and therapeutic effect of antiplatelet agents. 18, 19 Elevated soluble CD40 ligand levels indicated a significantly increased risk of death or nonfatal myocardial infarction. Furthermore, elevation of soluble CD40 ligand identifies a subgroup of patients at high risk who are likely to benefit from antiplatelet treatment with abciximab. 
